• OTS
  • May 31, 2019
SHARE
Post Views: 561

Malek-Adamian E, Fakhoury J, Arnold AE, Martínez-Montero S, Shoichet MS, Damha MJ.
Nucleic Acid Ther. 2019 May 14.

PubMed

Related articles

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

April 23rd, 2021
Non-specific interactions of antibody-oligonucleotide conjugates with living cells

Non-specific interactions of antibody-oligonucleotide conjugates with living cells

April 23rd, 2021
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

April 23rd, 2021
siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

March 15th, 2021
Perspectives on the Designation of Oligonucleotide Starting Materials

Perspectives on the Designation of Oligonucleotide Starting Materials

March 15th, 2021
Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs.

Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs.

March 15th, 2021